Literature DB >> 33824472

LncRNA SNHG6 promotes G1/S-phase transition in hepatocellular carcinoma by impairing miR-204-5p-mediated inhibition of E2F1.

Kai Chen1,2, Yifu Hou1,2, Rui Liao3, Youzan Li3, Hongji Yang4,5, Jun Gong6.   

Abstract

Emerging evidence suggests that long noncoding RNAs (lncRNAs) function as competitive endogenous RNA (ceRNA) targeting proteins and genes; however, the role of lncRNAs in hepatocellular carcinoma (HCC) is not well understood. We investigated the mechanism by which lncRNA SNHG6 promotes the development of HCC. RT-qPCR revealed upregulated lncRNA SNHG6 in the HCC setting. Elevated SNHG6 expression was indicative of poor prognosis in patients with HCC. SNHG6 overexpression resulted in increased cyclin D1, cyclin E1, and E2F1 expression both in vitro and in vivo. SNHG6 also promoted HCC cell proliferation by enhancing G1-S phase transition in vitro. Dual luciferase reporter assays, RIP, and RNA pull-down assays demonstrated SNHG6 competitively bound to miR-204-5p and inhibited its expression preventing miR-204-5p from targeting E2F1. Overexpression of miR-204-5p abolished the effect of SNHG6. Our data suggest that SNHG6 functions as a ceRNA that targets miR-204-5p resulting in an increased E2F1 expression and enhanced G1-S phase transition, thereby promoting the tumorigenesis of HCC.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33824472     DOI: 10.1038/s41388-021-01671-2

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  56 in total

Review 1.  Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications.

Authors:  Chun-Ming Wong; Felice Ho-Ching Tsang; Irene Oi-Lin Ng
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-01-10       Impact factor: 46.802

Review 2.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; María Reig; Jordi Bruix
Journal:  Lancet       Date:  2018-01-05       Impact factor: 79.321

3.  Long Non-Coding RNA SNHG6 as a Potential Biomarker for Hepatocellular Carcinoma.

Authors:  Maryam Tahmasebi Birgani; Mohammadreza Hajjari; Arman Shahrisa; Atefeh Khoshnevisan; Zahra Shoja; Paria Motahari; Baharak Farhangi
Journal:  Pathol Oncol Res       Date:  2017-05-15       Impact factor: 3.201

Review 4.  Long Noncoding RNAs: From Clinical Genetics to Therapeutic Targets?

Authors:  Reinier A Boon; Nicolas Jaé; Lesca Holdt; Stefanie Dimmeler
Journal:  J Am Coll Cardiol       Date:  2016-03-15       Impact factor: 24.094

5.  Up-regulation of SNHG6 activates SERPINH1 expression by competitive binding to miR-139-5p to promote hepatocellular carcinoma progression.

Authors:  Gang Wu; Xueming Ju; Youyu Wang; Zhixi Li; Xianfeng Gan
Journal:  Cell Cycle       Date:  2019-07-01       Impact factor: 4.534

Review 6.  Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.

Authors:  Tim F Greten; Chunwei Walter Lai; Guangfu Li; Kevin F Staveley-O'Carroll
Journal:  Gastroenterology       Date:  2018-10-01       Impact factor: 22.682

Review 7.  Long noncoding RNA, the methylation of genomic elements and their emerging crosstalk in hepatocellular carcinoma.

Authors:  Sheng-Xian Yuan; Jin Zhang; Qing-Guo Xu; Yuan Yang; Wei-Ping Zhou
Journal:  Cancer Lett       Date:  2015-08-14       Impact factor: 8.679

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 9.  A global view of hepatocellular carcinoma: trends, risk, prevention and management.

Authors:  Ju Dong Yang; Pierre Hainaut; Gregory J Gores; Amina Amadou; Amelie Plymoth; Lewis R Roberts
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08-22       Impact factor: 73.082

Review 10.  The role of long noncoding RNAs in hepatocellular carcinoma.

Authors:  Zhao Huang; Jian-Kang Zhou; Yong Peng; Weifeng He; Canhua Huang
Journal:  Mol Cancer       Date:  2020-04-15       Impact factor: 27.401

View more
  3 in total

1.  lncRNA MIAT targets miR-411-5p/STAT3/PD-L1 axis mediating hepatocellular carcinoma immune response.

Authors:  Xiaoxia Zhang; Banglun Pan; Jiacheng Qiu; Xiaoling Ke; Shuling Shen; Xiaoqian Wang; Nanhong Tang
Journal:  Int J Exp Pathol       Date:  2022-04-15       Impact factor: 2.793

2.  Long Non-Coding LEF1-AS1 Sponge miR-5100 Regulates Apoptosis and Autophagy in Gastric Cancer Cells via the miR-5100/DEK/AMPK-mTOR Axis.

Authors:  Huimin Zhang; Jun Wang; Yundan Wang; Jiapeng Li; Lili Zhao; Tongcun Zhang; Xinghua Liao
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

Review 3.  Current Research Progress of the Role of LncRNA LEF1-AS1 in a Variety of Tumors.

Authors:  Qingyuan Zheng; Xiao Yu; Menggang Zhang; Shuijun Zhang; Wenzhi Guo; Yuting He
Journal:  Front Cell Dev Biol       Date:  2021-12-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.